Actuate Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Selling, General & Admin	12.2	6.48	3.27	3.82
Research & Development	10.29	18.68	21.71	16.39
Total Operating Expenses	22.5	25.16	24.97	20.21
Operating Income	-22.5	-25.16	-24.97	-20.21
Interest Income	0.29	0.22	0.35	0.03
Interest Expense	-0.02	-0.02	-0.04	-0.02
Other Non-Operating Income (Expense)	-	-2.33	-0.08	0.04
Total Non-Operating Income (Expense)	0.27	-2.12	0.23	0.05
Pretax Income	-22.23	-27.29	-24.74	-20.16
Net Income	-22.23	-27.29	-24.74	-20.16
Net Income to Common	-22.23	-27.29	-24.74	-20.16
Shares Outstanding (Basic)	21	8	1	1
Shares Outstanding (Diluted)	21	8	1	1
Shares Change (YoY)	151.07%	483.48%	18.53%	-
EPS (Basic)	-1.06	-3.26	-17.24	-16.65
EPS (Diluted)	-1.06	-3.26	-17.24	-16.65
Shares Outstanding	23.25	19.53	1.69	1.69
Free Cash Flow	-19.21	-21.84	-21.63	-17.79
Free Cash Flow Per Share	-0.91	-2.61	-15.07	-14.70
EBITDA	-22.5	-25.16	-24.97	-20.21
EBIT	-22.5	-25.16	-24.97	-20.21

Updated Mar 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q